查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868247

血液傳染病檢查市場（按產品、技術、最終用戶和應用分類）—2025-2032年全球預測

Bloodstream Infection Testing Market by Product, Technology, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液傳染傳染病檢查市場將成長至 22.2 億美元，複合年成長率為 7.93%。

關鍵市場統計數據
基準年 2024 12億美元
預計年份：2025年 13億美元
預測年份 2032 22.2億美元
複合年成長率 (%) 7.93%

本文全面概述了臨床需求、實驗室操作和診斷技術創新如何融合，從而改變血液傳染病檢查的實踐。

血液感染疾病仍然是急診和公共衛生領域的核心挑戰，因此迫切需要診斷的準確性、速度和臨床整合。近年來，診斷格局已從漸進式的實驗室改進轉向更廣泛地關注快速、可操作的結果，這些結果能夠直接指導抗菌藥物管理和患者管理。隨著臨床醫生和實驗室負責人重新評估通訊協定，他們優先考慮那些能夠加快標靶治療速度，同時又能維持嚴格的品質和合規性標準的解決方案。

對推動血液感染診斷技術快速發展和新應用路徑的技術、臨床和監管轉折點進行策略分析

血液感染檢測領域正經歷著變革性的轉變，這主要得益於技術進步、臨床路徑的演變以及監管機構對更快、更有效診斷方法的推動。生物感測器設計、分子診斷和質譜分析的創新各自具有獨特的優勢。生物感測器簡化了樣本製備，並可實現快速檢測，通常可在床邊進行。分子診斷提高了靈敏度，並改善了病原體的鑑定。質譜分析可在既定的實驗室工作流程中實現物種層級的可靠鑑定。綜合運用這些技術，臨床醫師和實驗室技術人員可選擇的方案範圍正在不斷擴大。

評估2025年關稅調整對血液傳染傳染病檢查生態系的供應鏈韌性、籌資策略和營運計畫的影響。

近期關稅調整和貿易政策考量，特別是已宣布或正在考慮的2025年措施，對診斷耗材、儀器和組件的供應鏈產生了複雜的影響。關稅增加了進口試劑、一次性拋棄式和專用儀器零件的到岸成本，進而波及採購週期和庫存策略。為此，實驗室和製造商正努力透過審查籌資策略、增加國內庫存緩衝以及加快對替代供應商的資格認證，來降低對單一供應來源的依賴。

詳細的細分分析突顯了產品類別、平台技術、臨床環境和應用需求之間的交集，這些交集會影響產品的採用和投資決策。

有效的市場區隔揭示了臨床需求、技術能力和商業性機會的交集。透過對產品、技術、最終用戶和應用等維度的詳細分析，可以發現不同的採用模式。按產品類別分類，儀器吸引了尋求高通量和自動化的集中式實驗室的投資；試劑和試劑盒是耗材管理和經常性收入模式的核心；軟體則日益成為連接、分析和決策支援的基礎。每個產品類型都需要不同的服務模式和檢驗標準，進而影響採購和生命週期管理決策。

區域比較評估：報銷制度、監管重點與醫療服務模式對血流感染診斷採納和部署的影響

區域趨勢正在塑造需求模式和創新路徑，美洲、歐洲、中東和非洲以及亞太地區的營運重點各不相同。在美洲，醫療系統優先考慮將新的診斷方法快速整合到臨床通訊協定和以價值為導向的醫療服務舉措中，並評估其帶來的顯著療效提升。這促使人們關注能夠在診療現場提供可操作結果，同時又能維持實驗室級品質以進行確認性檢測的解決方案。

本文以產業視角，探討領先的診斷設備製造商如何調整其產品組合、夥伴關係和檢驗策略，以推動產品應用並確保業務永續營運。

為了應對速度和精確度的雙重挑戰，主要企業正在重新定義其策略，同時投資於能夠確保供應連續性和客戶成功的服務模式。一些企業專注於垂直整合解決方案，將儀器與專有試劑和數據分析相結合，以增強效能管理和生命週期效益。另一些企業則優先考慮開放平台互通性和策略合作夥伴關係，這可以加速市場准入，並降低擁有各種現有設備的實驗室採用新技術的門檻。

診斷開發人員和醫療保健領導者：關於加強血液感染檢測供應鏈韌性、臨床整合和實證醫學的實用優先建議

為了維持臨床服務的連續性和競爭優勢，產業領導者必須採取務實的態度，平衡短期營運需求和長期技術投資。優先考慮可整合到現有工作流程中的模組化解決方案，有助於實驗室減少營運中斷並減輕驗證負擔。同時，有針對性地投資自動化和試劑效率提升，可以保護營運免受供應波動的影響。同樣重要的是，制定多供應商籌資策略和完善的供應商選擇程序，以避免對單一供應商的依賴，並在市場波動期間維持檢測能力。

採用透明、以證據為導向的調查方法，整契約儕審查的研究、監管分析和相關人員訪談，確保獲得可靠且可操作的洞見。

本執行摘要的研究整合了同行評審文獻、監管指導文件、行業白皮書以及對臨床實驗室負責人、技術開發人員和採購專業人員的訪談，以確保觀點多元化。臨床檢驗研究和通訊協定審查的證據與營運報告和供應鏈分析進行交叉比對，以了解技術性能和實際應用挑戰。受訪者涵蓋了各種醫療機構，包括急診醫院實驗室、參考中心和照護現場，以確保研究結果能反映各種營運限制。

總之，該總結強調，技術創新、運作韌性和證據生成相結合是改善血液感染診斷結果的途徑。

整體而言，血液傳染病檢查領域正朝著更靈活、整合和主導的模式發展，強調在維持嚴格的分析性能和品管標準的同時，快速獲得具有臨床指導意義的結果。生物感測器、培養系統、質譜和分子診斷等多種技術為應對不同的臨床應用場景提供了互補途徑，而最成功的應用將是那些能夠將技術優勢與目標醫療環境的實際操作相結合的應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 次世代定序平台整合到血液感染疾病診斷中，用於快速病原體鑑定
  • 新興的抗菌藥物抗藥性分析檢測指南敗血症患者的個人化抗生素治療
  • 引入照護現場分子診斷設備，以加速加護治療病房中血流感染疾病的檢測。
  • 開發一種多重免疫檢測試劑盒，用於同時檢測血液感染疾病中的細菌和真菌病原體
  • 推出用於血液感染管理遠端監測和數據整合的數位健康平台
  • 微流體實驗室晶片技術在自動化血液樣本病原體富集和鑑定方面的進展
  • 監管獎勵和報銷改革，以促進醫院採用新型血液感染檢測診斷方法

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品分類的血液傳染病檢查市場

  • 裝置
  • 試劑和試劑盒
  • 軟體

9. 按技術分類的血液傳染病檢查市場

  • 生物感測器平台
    • 電化學生物感測器
    • 光學生物感測器
  • 基於文化的系統
    • 自動化培養系統
    • 手工培養方法
  • 質譜分析
    • MALDI-TOF質譜
  • 分子診斷
    • 次世代定序
    • PCR

第10章 按最終用戶分類的血液傳染病檢查市場

  • 學術和研究機構
  • 醫院檢查室
  • 就地檢驗
  • 參考實驗室

第11章 依應用分類的血液傳染病檢查市場

  • 臨床診斷
  • 研究
  • 監視和監測

第12章 各地區血液傳染病檢查市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血液傳染病檢查市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國血液傳染病檢查市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Becton Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Luminex Corporation
    • QIAGEN NV
Product Code: MRR-4D00F1312BD4

The Bloodstream Infection Testing Market is projected to grow by USD 2.22 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2032] USD 2.22 billion
CAGR (%) 7.93%

A comprehensive situational overview describing how clinical demand, laboratory operations, and diagnostic innovation are converging to transform bloodstream infection testing practices

Bloodstream infections remain a central challenge for acute care and public health, driving urgent demands on diagnostic accuracy, speed, and clinical integration. Over recent years, the diagnostic landscape has shifted from incremental laboratory improvements to a broader emphasis on rapid, actionable results that can directly inform antimicrobial stewardship and patient management. As clinicians and laboratory leaders reassess protocols, they prioritize solutions that shorten time to targeted therapy while maintaining rigorous quality and compliance standards.

The adoption of advanced diagnostics is reshaping workflows, with laboratories balancing the need for high-throughput capacity alongside the demand for near-patient testing in emergency and critical care environments. At the same time, research institutions and reference laboratories continue to push technical boundaries, validating new biomarkers and sequencing approaches that promise deeper etiological insights. These changes are occurring in a context of constrained budgets, heightened regulatory scrutiny, and supply chain sensitivities, which together create both obstacles and incentives for innovative providers.

Consequently, stakeholders must consider a diverse set of factors when evaluating diagnostic strategies: analytical performance, integration with electronic health records and laboratory information systems, operational impact on staffing and turnaround times, and the ability to support surveillance and public health reporting. The resulting priorities emphasize not only technological capability but also usability, interoperability, and proven clinical utility across varied care settings.

A strategic analysis of the technological, clinical, and regulatory inflection points driving rapid evolution and new adoption pathways in bloodstream infection diagnostics

The landscape of bloodstream infection testing is undergoing transformative shifts driven by converging technological advances, evolving clinical pathways, and regulatory momentum toward faster, more actionable diagnostics. Innovations in biosensor design, molecular methods, and mass spectrometry are each contributing distinct advantages: biosensors enable rapid, often bedside detection with reduced sample preparation; molecular diagnostics offer enhanced sensitivity and pathogen identification precision; and mass spectrometry provides robust species-level identification in established laboratory workflows. Taken together, these technologies are expanding the palette of options available to clinicians and laboratorians.

Alongside technical progress, there is a sustained clinical trend toward earlier targeted therapy, underpinned by growing antimicrobial stewardship programs that demand diagnostic evidence to justify narrower-spectrum treatments. This creates a feedback loop: as diagnostics deliver actionable results more quickly, clinical protocols adjust to leverage those results, which in turn drives demand for even faster and more integrated testing solutions. Regulatory frameworks and reimbursement policies are beginning to reflect this shift, increasingly rewarding demonstrable improvements in patient outcomes and system efficiencies rather than raw throughput alone.

Operationally, laboratories are rethinking workflows to incorporate modular testing strategies that balance central laboratory capacity with decentralized point-of-care options. Interoperability with laboratory information systems and electronic health records has become a critical enabler of rapid result distribution and decision support. At the same time, developers and providers are paying closer attention to usability, automation, and supply continuity to reduce the burden on constrained clinical teams. These combined forces are not only changing product roadmaps but also influencing procurement criteria, partnership models, and long-term clinical adoption pathways.

An evaluation of how 2025 tariff shifts have reshaped supply chain resilience, procurement strategies, and operational planning across the bloodstream infection testing ecosystem

Recent tariff adjustments and trade policy considerations, especially measures announced or contemplated in 2025, have created a complex overlay on supply chains for diagnostic consumables, instruments, and components. Tariffs can increase landed costs for imported reagents, single-use disposables, and specialized instrument parts, which then reverberate across procurement cycles and inventory strategies. Laboratories and manufacturers have responded by reassessing sourcing strategies, increasing onshore inventory buffers, and accelerating qualification of alternative suppliers to mitigate single-source dependencies.

These dynamics have practical implications for procurement timelines and capital allocation. Buyers may shift toward longer contracts with domestic or tariff-exempt suppliers, preferring predictable supply terms over marginal cost advantages. Meanwhile, manufacturers face pressure to optimize manufacturing footprints, balance production between domestic and international sites, and adjust pricing structures to preserve commercial viability without undermining customer relationships. In some cases, tariffs have incentivized localized assembly or component manufacturing to reduce exposure to cross-border levies and promote supply resilience.

Beyond direct cost implications, tariff-driven realignments affect innovation velocity and collaboration models. Companies may defer noncritical upgrades or slow international rollouts while reassessing cost models. Conversely, some organizations accelerate investments in automation and reagent efficiency to lower per-test variable costs and sidestep tariff escalations. For clinical laboratories, the cumulative impact has been a renewed focus on operational flexibility: multi-vendor procurement strategies, increased validation of platform interchangeability, and strategic stockpiling where feasible to avoid diagnostic interruptions. These adaptations aim to preserve clinical continuity while managing budgetary constraints and regulatory compliance amid an evolving trade environment.

A detailed segmentation-driven perspective revealing where product classes, platform technologies, care settings, and application needs intersect to influence adoption and investment decisions

Effective segmentation reveals where clinical need, technical capability, and commercial opportunity intersect, and a nuanced view across product, technology, end user, and application slices illuminates distinct adoption patterns. When analyzed by product, instruments attract investments from centralized laboratories seeking throughput and automation, reagents and kits are focal for consumables management and recurring revenue models, and software increasingly underpins connectivity, analytics, and decision support. Each product category demands different service models and validation criteria, influencing procurement and lifecycle management decisions.

Considering technology, biosensor platforms offer rapid, often near-patient detection and are evolving along electrochemical and optical modalities that favor different sample types and use cases. Culture based systems remain foundational for pathogen isolation and susceptibility testing, with automated culture systems streamlining workflow and manual culture methods retaining relevance in resource-constrained settings. Mass spectrometry, particularly MALDI ToF MS, has become a workhorse for species identification where laboratory throughput and accuracy are paramount. Molecular diagnostics, including next generation sequencing and PCR, deliver deep pathogen characterization and resistance profiling, supporting both clinical decision-making and surveillance objectives.

From an end-user perspective, academic and research institutes continue to advance method development and validation studies, hospital laboratories focus on integrating rapid diagnostics into care pathways to reduce length of stay and improve outcomes, point of care testing brings immediacy to emergency and critical care settings where time is critical, and reference laboratories concentrate on specialized testing, confirmation, and epidemiological support. Application-driven segmentation differentiates clinical diagnosis needs from research priorities and surveillance and monitoring obligations, each with distinct performance, throughput, and regulatory demands. Understanding these intersecting segments helps stakeholders prioritize investments that match technical strengths to user needs and application constraints.

A comparative regional assessment describing how reimbursement, regulatory priorities, and healthcare delivery models shape the adoption and deployment of bloodstream infection diagnostics

Regional dynamics shape both demand patterns and innovation pathways, with distinct operational priorities in the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems emphasize rapid integration of new diagnostics into clinical protocols and value-based care initiatives that reward demonstrable outcome improvements. This drives interest in solutions that can provide actionable results at the point of care while maintaining laboratory-level quality for confirmatory testing.

In Europe, Middle East & Africa, regulatory harmonization efforts and national public health priorities guide procurement and adoption, and there is marked interest in diagnostics that can support surveillance networks and antimicrobial resistance monitoring across diverse care environments. Meanwhile, Asia-Pacific exhibits strong demand for scalable, cost-efficient testing solutions that can meet both high-volume urban centers and resource-limited rural settings. Market participants across all regions are negotiating trade-offs between centralized high-throughput platforms and decentralized rapid tests to optimize clinical pathways and resource utilization.

Across geographies, interoperability with health IT infrastructure, supply chain robustness, and local manufacturing considerations influence deployment strategies. Regional reimbursement frameworks and public health policy also determine how quickly novel diagnostics move from validation to routine use, with some jurisdictions prioritizing immediate clinical impact and others focusing on longer-term surveillance capabilities. These regional nuances require tailored commercial approaches and regulatory planning to ensure successful technology adoption and sustained clinical integration.

An industry-focused examination of how leading diagnostics organizations are aligning product, partnership, and evidence strategies to accelerate uptake and secure operational resilience

Leading players are redefining their strategies to address the dual imperatives of speed and accuracy while also investing in service models that ensure supply continuity and customer success. Some firms are concentrating on vertically integrated solutions that pair instruments with proprietary reagents and data analytics, enabling a tighter control of performance and lifecycle revenue. Others prioritize open-platform interoperability and strategic partnerships that accelerate market access and lower barriers to adoption for laboratories with diverse existing equipment.

Collaboration between technology providers, clinical networks, and academic centers is becoming more common, as companies seek real-world evidence and validation studies that demonstrate clinical utility and support regulatory submissions. Investment in software and informatics capabilities is another notable trend: advanced laboratory information management integration, result interpretation algorithms, and antimicrobial stewardship decision support are increasingly valued additions to core diagnostic offerings. Companies are also exploring business models that reduce upfront capital burdens for customers, including reagent-as-a-service or outcome-linked agreements, to facilitate uptake in budget-constrained environments.

In parallel, many organizations are enhancing their global supply chain strategies to mitigate tariff exposure and logistical disruptions. This includes diversifying supplier bases, locating critical manufacturing closer to key markets, and strengthening distribution partnerships. Together, these strategic moves reflect a competitive environment where differentiation rests on a combination of technological performance, evidence generation, customer support, and operational reliability.

Practical, prioritized recommendations for diagnostic developers and healthcare leaders to strengthen supply resilience, clinical integration, and evidence generation for bloodstream infection testing

Industry leaders should adopt a pragmatic approach that balances near-term operational needs with long-term technological investments to preserve both clinical continuity and competitive advantage. Prioritizing modular solutions that can be integrated into existing workflows reduces disruption and lowers validation overhead for laboratories, while investing selectively in automation and reagent efficiency helps insulate operations from supply volatility. Equally important is building multi-vendor procurement strategies and robust supplier qualification programs to avoid single-source dependencies and to sustain testing capacity during market shifts.

Strategic partnerships with clinical networks and academic collaborators will accelerate real-world evidence generation, which in turn supports regulatory submissions and payer dialogues. Investing in software and interoperability pays dividends by improving result routing, analytics, and stewardship integration; these capabilities enhance clinical utility and create stickiness for customers. Finally, scenario-based planning for trade and tariff impacts - including localized manufacturing where feasible and flexible contracting models - will reduce operational risk and preserve access to critical consumables during periods of policy uncertainty.

A transparent and evidence-driven methodology integrating peer-reviewed research, regulatory analysis, and stakeholder interviews to ensure robust and actionable insights

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance documents, industry white papers, and interviews with clinical laboratory leaders, technology developers, and procurement specialists to ensure a rounded perspective. Evidence from clinical validation studies and protocol reviews was cross-checked against operational reports and supply chain analyses to understand both technical performance and real-world implementation challenges. Interview subjects were selected to represent a diversity of care settings, including acute hospital laboratories, reference centers, and point-of-care environments, ensuring that findings reflect varied operational constraints.

Where possible, technical claims and adoption trends were corroborated by independent publications and regulatory filings to avoid reliance on promotional materials. The methodology prioritized transparency in source selection and clearly documented assumptions related to technology capabilities, regulatory context, and logistical constraints. This approach provides readers with a defensible analytical foundation for decision-making while acknowledging areas where further primary research or longitudinal data would strengthen confidence in long-term trends.

A concluding synthesis highlighting the convergence of technological innovation, operational resilience, and evidence generation as the pathway to improved diagnostic outcomes in bloodstream infections

In aggregate, the field of bloodstream infection testing is moving toward a more agile, integrated, and evidence-driven model that privileges rapid, clinically actionable results while maintaining rigorous standards for analytical performance and quality control. Technological diversity-spanning biosensors, culture systems, mass spectrometry, and molecular diagnostics-offers complementary routes to address different clinical use cases, and the most successful implementations will be those that align technical strengths with the operational realities of the targeted care environment.

At the same time, external pressures such as tariff changes, supply chain fragility, and evolving reimbursement priorities underscore the need for flexible procurement strategies and resilient operational planning. Organizations that invest in interoperability, real-world evidence generation, and strategic supplier relationships will be better positioned to deliver consistent diagnostic value. Ultimately, the path to improved patient outcomes hinges on aligning product innovation with clinical workflows, regulatory requirements, and pragmatic commercial models that enable sustainable adoption across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of next-generation sequencing platforms for rapid pathogen identification in bloodstream infection diagnostics
  • 5.2. Emergence of antimicrobial resistance profiling assays to guide personalized antibiotic therapy in sepsis patients
  • 5.3. Adoption of point-of-care molecular diagnostic devices to accelerate bloodstream infection detection in critical care settings
  • 5.4. Development of multiplex immunoassay panels for simultaneous detection of bacterial and fungal pathogens in blood infections
  • 5.5. Implementation of digital health platforms for remote monitoring and data integration in bloodstream infection management
  • 5.6. Advancements in microfluidic lab-on-a-chip technologies for automated pathogen enrichment and identification from blood samples
  • 5.7. Regulatory incentives and reimbursement reforms driving adoption of novel diagnostics for bloodstream infection testing in hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bloodstream Infection Testing Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software

9. Bloodstream Infection Testing Market, by Technology

  • 9.1. Biosensor Platforms
    • 9.1.1. Electrochemical Biosensors
    • 9.1.2. Optical Biosensors
  • 9.2. Culture Based Systems
    • 9.2.1. Automated Culture Systems
    • 9.2.2. Manual Culture Methods
  • 9.3. Mass Spectrometry
    • 9.3.1. MALDI ToF Ms
  • 9.4. Molecular Diagnostics
    • 9.4.1. Next Generation Sequencing
    • 9.4.2. PCR

10. Bloodstream Infection Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospital Laboratories
  • 10.3. Point Of Care Testing
  • 10.4. Reference Laboratories

11. Bloodstream Infection Testing Market, by Application

  • 11.1. Clinical Diagnosis
  • 11.2. Research
  • 11.3. Surveillance & Monitoring

12. Bloodstream Infection Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bloodstream Infection Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bloodstream Infection Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Becton Dickinson and Company
    • 15.3.2. bioMerieux SA
    • 15.3.3. F. Hoffmann-La Roche AG
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. Abbott Laboratories
    • 15.3.7. Danaher Corporation
    • 15.3.8. Bio-Rad Laboratories, Inc.
    • 15.3.9. Luminex Corporation
    • 15.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION,